FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting
Executive Summary
Drug treatments and biomarker development for Alzheimer's disease are on the agenda of a meeting FDA expects to hold in October with neurology organizations, Janet Woodcock, the agency's chief medical officer, said during a July 25 audio conference sponsored by Avalere
You may also be interested in...
Alzheimer’s Biomarker Data Ready For Release; Analyses Pose Next Challenge
Biomarker data for Alzheimer's disease will be publicized early this year, one of a number of government and private efforts aimed at pushing research forward in 2008
Alzheimer’s Biomarker Data Ready For Release; Analyses Pose Next Challenge
Biomarker data for Alzheimer's disease will be publicized early this year, one of a number of government and private efforts aimed at pushing research forward in 2008
The cost of Alzheimer’s
The Congressional Budget Office estimates that the Alzheimer's Breakthrough Act of 2007 would authorize the appropriation of $24 million in fiscal year 2008 with an estimated $3.9 billion in total appropriations expected through 2012. The Act, sponsored by Sens. Barbara Mikulski, D-Md., and Kit Bond, R-Mo., would provide more funds for disease research, public education and an Alzheimer's call center, as well as state demonstration projects. Though no legislative action is planned for the bill, FDA plans to hold an Oct. meeting with neurology organizations to discuss drug treatments and biomarker developments for the disease (1"The Pink Sheet" Aug. 13, 2007, p. 10)...